Atlantic Therapeutics develops Innovo, a wearable pelvic‑floor neuromuscular electrical stimulation solution delivered via a shorts-style garment containing multiple electrodes. The company spun out from Bio-Medical Research Group, the maker of Slendertone, and has pursued a direct-to-consumer sales model. Innovo received FDA approval and was launched in the US in early 2020. Management reported US sales rose 250% year-over-year. The company cites a large addressable market—about one in three women experience stress urinary incontinence while only one in four seek medical attention. The most recent publicly available accounts show accumulated losses of €9.6 million as of February 2020. Atlantic Therapeutics develops INNOVO, a non-invasive wearable neuromuscular electrical stimulation (NMES) system delivered via exercise shorts to treat female stress urinary incontinence. INNOVO is FDA-approved in the United States and company-cited clinical data showed 80% of users experienced significant improvements after four weeks and 87% were “dry” or “near dry” after three months. The company positions INNOVO as a paradigm shift in the $13bn urinary incontinence market, providing an alternative to pads by strengthening and re-educating pelvic floor muscles. Atlantic Therapeutics is headquartered in Galway, Ireland and has operations in Boston, MA, and develops consumer medical devices, software, apps and connected health technologies for incontinence. The recent financing will support expansion of commercialization activities in core US and UK markets and accelerate the launch of a next-generation product later this year. The company has attracted international VC investment and enterprise grant funding and says it is poised to establish itself as a leading Femtech solution provider to treat stress urinary incontinence. Atlantic Therapeutics develops professional and consumer medical devices, software, apps and connected health technologies to treat incontinence and related pelvic floor disorders. Its core product, INNOVO®, is a unique, externally applied, patented CE device that delivers garment-based pelvic floor muscle strengthening and nerve stimulation therapy for use at home. The company says INNOVO® treats the cause of bladder leaks and has already helped thousands of people in Europe. Atlantic Therapeutics plans to enter the US market following recent FDA clearance for INNOVO®, accelerate sales in other geographies, further develop its product portfolio, and expand into new clinical applications. The company raised capital in a Series B to support these commercial and product development plans. The business is headquartered in Galway, Ireland. Atlantic Therapeutics is a Galway-based medical device company that develops non-invasive pelvic floor strengthening and nerve stimulation products built on its Innovo technology platform. The company spun out from Bio-medical Research Group (BMR), which retains a minority shareholding. It has completed a €15m growth capital financing and also secured loan capital from Silicon Valley Bank. Equity investors include Seroba Life Sciences and Earlybird Venture Capital, with Seroba co-leading the round. The capital will be used to accelerate market and geographic expansion, support new product development, and conclude a clinical study in support of an FDA submission for U.S. regulatory clearance. Atlantic Therapeutics also plans further trials to expand the use of its technology to additional indications.

Total raised

$71M

Funding rounds

5

Latest round

Equity

Latest activity

Jan 2022